Ann: Drug Delivery Greater Than 100% More Effective In Animals, page-38

I think by the looks of things Sarepta is really just pivoted and building itself into a Gene Therapy power house …. they are certainly the drugs they are leading with in clinic now & over the past 2 years Sarepta has signed 6 ? 7 ? deals all of which have been on building their gene therapy position - no deals outside of that.

Did they take anything at the end of the 4 year collaboration with MU, Fletcher / Wilton and establishing STL ? By the looks of it no, unless all parties are keeping it quiet ? Would be interesting to know if STL stayed active ? Although I would assume any extension would have been released ?